Meghan Dozier, APRN
Family · Cincinnati, OHNPI 1649797366
Payments from drug & device makers
Across 71 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$181
- AstraZeneca$179
- Novo Nordisk$93
- Pfizer$84
- Johnson & Johnson$46
- Amgen$42
- plus $451 from 21 others
What the payments were for
- Food & beverage$1,078100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 13 | $181 |
| AstraZeneca | 12 | $179 |
| Novo Nordisk | 6 | $93 |
| Pfizer | 5 | $84 |
| Johnson & Johnson | 3 | $46 |
| Amgen | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Lilly USA, LLC | 2 | $39 |
| Alpha Cognition USA, Inc. | 3 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Boston Scientific | 2 | $31 |
| Astellas Pharma US Inc | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Acadia Pharmaceuticals Inc | 1 | $27 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Medtronic | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$1,078 in reported general payments places this provider in the 70th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 35 | $130,438 |
| AustedoDeutetrabenazine | 29 | $119,646 |
| OtezlaApremilast | 57 | $117,441 |
| EliquisApixaban | 303 | $90,502 |
| RestasisCyclosporine | 90 | $31,767 |
| Memantine Hcl | 317 | $27,345 |
| LinzessLinaclotide | 47 | $27,021 |
| BriviactBrivaracetam | 45 | $26,344 |
| XareltoRivaroxaban | 78 | $24,827 |
| JanuviaSitagliptin Phosphate | 65 | $18,481 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 86 | $18,362 |
| FarxigaDapagliflozin Propanediol | 63 | $18,338 |
| TradjentaLinagliptin | 61 | $15,880 |
| JardianceEmpagliflozin | 51 | $15,259 |
| LokelmaSodium Zirconium Cyclosilicate | 35 | $15,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $15 | $119,64629 claims |
| AmgenOtezla | $42 | $117,44157 claims |
| PfizerEliquis, Abrysvo | $84 | $104,069346 claims |
| AbbVieRestasis, Linzess | $181 | $58,789137 claims |
| Boehringer IngelheimTradjenta, Jardiance, Combivent Respimat | $13 | $38,425126 claims |
| AstraZenecaFarxiga, Lokelma | $179 | $33,39198 claims |
| Johnson & JohnsonXarelto | $46 | $24,82778 claims |
| BayerKerendia | $14 | $9,21133 claims |
| Astellas Pharma US IncMyrbetriq | $27 | $4,92122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,812 family providers in Ohio.
Other family in Cincinnati
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Lindsey SpencerCincinnati$53K
- Bria BarjucaCincinnati$38K
- Jillian CowanCincinnati$20K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.